Por favor, use este identificador para citar o enlazar este ítem: http://conacyt.repositorioinstitucional.mx/jspui/handle/1000/1984
The FDA-approved gold drug Auranofin inhibits novel coronavirus (SARS-COV-2) replication and attenuates inflammation in human cells
Hussin Rothan.
Shannon Stone.
Janhavi Natekar.
Pratima Kumari.
Komal Arora.
Mukesh Kumar.
Acceso Abierto
Atribución-NoComercial-SinDerivadas
10.1101/2020.04.14.041228
SARS-COV-2 has recently emerged as a new public health threat. Herein, we report that the FDA-approved gold drug, auranofin, inhibits SARS-COV-2 replication in human cells at low micro molar concentration. Treatment of cells with auranofin resulted in a 95% reduction in the viral RNA at 48 hours after infection. Auranofin treatment dramatically reduced the expression of SARS-COV-2-induced cytokines in human cells. These data indicate that auranofin could be a useful drug to limit SARS-CoV-2 infection and associated lung injury due to its anti-viral, anti-inflammatory and anti-ROS properties. Auranofin has a well-known toxicity profile and is considered safe for human use.
www.biorxiv.org
2020
Artículo
https://www.biorxiv.org/content/10.1101/2020.04.14.041228v1.full.pdf
Inglés
VIRUS RESPIRATORIOS
Aparece en las colecciones: Artículos científicos

Cargar archivos:


Fichero Tamaño Formato  
1100743.pdf1.98 MBAdobe PDFVisualizar/Abrir